Bayer’s plan to contain still spiraling suits against glyphosate

Bayer will “significantly contain” glyphosate litigation by the end of 2026, CEO Bill Anderson said … during the company’s second-quarter 2025 earnings call.

“Every decision we make has the goal of positioning the company to move past our litigation woes.”

The company has repeatedly said this litigation—which has been ongoing since Bayer acquired Monsanto in 2018—is “a huge burden” on company financials thanks to payouts to plaintiffs alleging that the weed killer caused them to develop cancer.

Bayer has repeatedly said it stands behind “the safety and non-carcinogenicity” of glyphosate.

The company is currently awaiting word from the Solicitor General as to whether the supreme court will take up [a] case—in which the plaintiff sued after attributing his non-Hodgkin’s lymphoma to Roundup exposure—around an appeal of a lower court’s $1.25 million verdict in a Missouri state court.

Related on the SLP

Daubert for Dummies—Scientific Reliability in U.S. Courts: Daubert, Rule 702, and Made-for-Litigation Evidence Glyphosate’s climate dividend: Weedkiller reduces greenhouse pollution equal to taking 21.8 million cars off the road each year

Guinea-Bissau halts widely condemned RFK Jr.-backed vaccine trial that would have withheld life-saving vaccines from thousands of newborns

‘Disillusioned’: Controversial RFK Jr. ally and MAHA leader Calley Means quits Trump advisory role

Supreme Court blocks Trump’s order halting transgender surgeries and hormone treatments for inmates

…

“We welcome this step, and we expect a recommendation in the coming weeks or months,” Anderson said of SCOTUS asking for input from the Solicitor General.

“This decision keeps intact the broader timeline of having a SCOTUS ruling by summer of next year.”

This is an excerpt. Read the original post here